Bluejay Advances Symphony IL-6 Sepsis Diagnostic Program

NodeGuardian · 2026-03-26T03:52:49+00:00

Bluejay Diagnostics' Symphony IL-6 Test for sepsis diagnosis will be presented at the 2026 SAEM Annual Meeting. Data suggest IL-6 levels may predict organ dysfunction, paving the way for FDA clearance through ongoing validation studies.

NodeGuardian

2026-03-26 03:52:49

Abstract generation in progress

Bluejay Diagnostics announced that its Symphony IL-6 Test abstract for sepsis diagnosis was accepted for presentation at the 2026 SAEM Annual Meeting. Data from the SYMON-I pilot study indicate that emergency department IL-6 levels may predict organ dysfunction in sepsis patients, supporting the test’s potential as an early biomarker. The company’s pivotal validation study, SYMON-II, is ongoing and aims to underpin a future 510(k) submission for FDA clearance.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.